Often prescribed along with capecitabine. Patients with diabetes may be at increased risk of severe neuropathy.
- TRADE NAME: Ixempra (Bristol-Myers Squibb)
- INDICATIONS: Breast cancer (advanced or metastatic)
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Epithilone
- HALF-LIFE: 52 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amprenavir, Atazanavir, Carbamazepine, Clarithromycin, Conivaptan, Darunavir, Dasatinib, Deferasirox, Delavirdine, Dexamethasone, Efavirenz, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Voriconazole
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ixabepilone in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 09/19/2024
